THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRYTaylor Francishtp5/doi.org/10.1080/15622975.2023.2179663REVIEW ARTICLEOPEN ACCESS價Check for updatesWorld Federation of Societies of Biological Psychiatry (WFSBP)guidelinesupdate 2023 on the pharmacological treatment of eating disordersHubertus Himmerichb Yael Doreen Lewisd,Chiara Contie,Hiba Mutwalliaf,Andreas Karwautz9,Jan Magnus Sjogren",Maria Mercedes Uribe Isaza',Marta Tyszkiewicz-Nwafor,Martin Aigner,Susan L.McElroy m D,Janet Treasureb and Siegfried Kasper;The WFSBP Task Force on Eating Disorders*Department of Psychological Medicine,Institute of Psychiatry,Psychology Neuroscience King's College London,London,UK;PSouth London and Maudsley NHS Foundation Trust,Bethlem Royal Hospital,Beckenham,UK;Hadarim Eating Disorders Unit,Shalvata Mental Health Center,Hod HaSharon,Israel:Sackler Faculty of Medicine,Tel Aviv University,Tel Aviv,Israel;Departmentof Psychological,Health,and Territorial Sciences,University "G.d'Annunzio"of Chieti-Pescara,Chieti,Italy;'Department of ClinicalNutrition,College of Applied Medical Sciences,Imam Abdulrahman Bin Faisal University,Dammam,Saudi Arabia;9Eating DisordersCare Research Unit,Department of Child and Adolescent Psychiatry,Medical University of Vienna,Vienna,Austria;"Institute forClinical Science,Umea University,Umea,Sweden;'Universidad Nacional de Colombia,Bogota,Colombia;Department of Child andAdolescent Psychiatry,Poznan University of Medical Sciences,Poznan,Poland;Universitatsklinikum Tulln,Tulln an der Donau,Austria;Lindner Center of HOPE,Mason,OH,USA;University of Cincinnati College of Medicine,Cincinnati,OH,USA;"Center forBrain Research,Medical University of Vienna,Vienna,AustriaABSTRACTARTICLE HISTORYObjectives:This 2023 update of the WFSBP guidelines for the pharmacological treatment ofReceived 8 February 2023eating disorders(EDs)reflects the latest diagnostic and psychopharmacological progress and theAccepted 8 February 2023improved WFSBP recommendations for the assessment of the level of evidence (LoE)and thegrade of recommendation(GoR).KEYWORDSMethods:The WFSBP Task Force EDs reviewed the relevant literature and provided a timelyGuidelines;pharmacologicaltreatment;anorexiagrading of the LoE and the GoR.nervosa;bulimia nervosa;Results:In anorexia nervosa (AN),only a limited recommendation (LoE:A;GoR:2)for olanzapinebinge-eating disordercan be given,because the available evidence is restricted to weight gain,and its effect on psy-chopathology is less clear.In bulimia nervosa(BN),the current literature prompts a recommen-dation for fluoxetine (LoE:A;GoR:1)or topiramate (LoE:A:GoR:1).In binge-eating disorder(BED),lisdexamfetamine (LDX;LoE:A;GoR:1)or topiramate (LoE:A;GoR:1)can be recom-mended.There is only sparse evidence for the drug treatment of avoidant restrictive food intakedisorder (ARFID),pica,and rumination disorder (RD).Conclusion:In BN,fluoxetine,and topiramate,and in BED,LDX and topiramate can be recom-mended.Despite the published evidence,olanzapine
